Compare US Global Jets ETF (JETS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs 10X Genomics Inc — how do they compare? US Global Jets ETF trades at $27.7 (market cap $878.48M), while 10X Genomics Inc trades at $79.4 (market cap $9.92B). The key difference: 10X Genomics Inc is far larger — about 11.3× US Global Jets ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and 10X Genomics Inc for 92 Days on average.
| JETS | TXG | |
|---|---|---|
Market Cap | $878.48M | $9.92B |
Volume | 4,402,990 | 9,372,166 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $97.74 |
52-Week Low | $23.64 | $11.48 |
Typical Hold Time | 26 Days | 92 Days |
Enterprise Value | — | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Recent news highlights underperformance versus aerospace/defense ETFs, with competitors like ARKX and ITA showing stronger returns. Technical indicators show oversold conditions on short-term RSI but overall bearish momentum from moving averages.
The outlook remains challenged by fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term support at $27 could provide a technical floor, but sustained recovery requires easing of fuel cost pressures and improved airline earnings visibility. The ETF's concentration in pure airline operators increases sensitivity to industry-specific risks.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
